These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31518073)

  • 1. Serum neurofilament heavy chains as early marker of motor neuron degeneration.
    De Schaepdryver M; Goossens J; De Meyer S; Jeromin A; Masrori P; Brix B; Claeys KG; Schaeverbeke J; Adamczuk K; Vandenberghe R; Van Damme P; Poesen K
    Ann Clin Transl Neurol; 2019 Oct; 6(10):1971-1979. PubMed ID: 31518073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    De Schaepdryver M; Jeromin A; Gille B; Claeys KG; Herbst V; Brix B; Van Damme P; Poesen K
    J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):367-373. PubMed ID: 29054919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis.
    McCombe PA; Pfluger C; Singh P; Lim CY; Airey C; Henderson RD
    J Neurol Sci; 2015; 353(1-2):122-9. PubMed ID: 25958264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Neurofilaments May Discriminate Upper Motor Neuron Syndromes: A Pilot Study.
    Zucchi E; Bedin R; Fasano A; Fini N; Gessani A; Vinceti M; Mandrioli J
    Neurodegener Dis; 2018; 18(5-6):255-261. PubMed ID: 30428468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
    Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
    Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.
    Feneberg E; Oeckl P; Steinacker P; Verde F; Barro C; Van Damme P; Gray E; Grosskreutz J; Jardel C; Kuhle J; Koerner S; Lamari F; Amador MDM; Mayer B; Morelli C; Muckova P; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Stubendorff B; Turner MR; Verbeek MM; Weishaupt JH; Weydt P; Ludolph AC; Otto M
    Neurology; 2018 Jan; 90(1):e22-e30. PubMed ID: 29212830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Shahim P; Norato G; Sinaii N; Zetterberg H; Blennow K; Chan L; Grunseich C
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.
    Gille B; De Schaepdryver M; Goossens J; Dedeene L; De Vocht J; Oldoni E; Goris A; Van Den Bosch L; Depreitere B; Claeys KG; Tournoy J; Van Damme P; Poesen K
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):291-304. PubMed ID: 29908069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of plasma phosphorylated neurofilament heavy chain (pNfH) in amyotrophic lateral sclerosis.
    Zecca C; Dell'Abate MT; Pasculli G; Capozzo R; Barone R; Arima S; Pollice A; Brescia V; Tortelli R; Logroscino G
    J Cell Mol Med; 2022 Jul; 26(13):3608-3615. PubMed ID: 35715961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.
    Wilke C; Pujol-Calderón F; Barro C; Stransky E; Blennow K; Michalak Z; Deuschle C; Jeromin A; Zetterberg H; Schüle R; Höglund K; Kuhle J; Synofzik M
    Clin Chem Lab Med; 2019 Sep; 57(10):1556-1564. PubMed ID: 31251725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pNfH is a promising biomarker for ALS.
    Ganesalingam J; An J; Bowser R; Andersen PM; Shaw CE
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Mar; 14(2):146-9. PubMed ID: 23134506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease.
    Falzone YM; Domi T; Agosta F; Pozzi L; Schito P; Fazio R; Del Carro U; Barbieri A; Comola M; Leocani L; Comi G; Carrera P; Filippi M; Quattrini A; Riva N
    J Neurol; 2020 Aug; 267(8):2272-2280. PubMed ID: 32306171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis.
    Chen X; Chen Y; Wei Q; Ou R; Cao B; Zhao B; Shang HF
    BMC Neurol; 2016 Sep; 16():173. PubMed ID: 27634542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
    Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY
    Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.
    Benatar M; Macklin EA; Malaspina A; Rogers ML; Hornstein E; Lombardi V; Renfrey D; Shepheard S; Magen I; Cohen Y; Granit V; Statland JM; Heckmann JM; Rademakers R; McHutchison CA; Petrucelli L; McMillan CT; Wuu J;
    EBioMedicine; 2024 Oct; 108():105323. PubMed ID: 39270623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of neurofilaments in differentiating motor neuron disease from multifocal motor neuropathy.
    Wohnrade C; Seeliger T; Gingele S; Bjelica B; Skripuletz T; Petri S
    J Neurol; 2024 Jul; 271(7):4441-4452. PubMed ID: 38683209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.
    Ganesalingam J; An J; Shaw CE; Shaw G; Lacomis D; Bowser R
    J Neurochem; 2011 May; 117(3):528-37. PubMed ID: 21418221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
    Benatar M; Zhang L; Wang L; Granit V; Statland J; Barohn R; Swenson A; Ravits J; Jackson C; Burns TM; Trivedi J; Pioro EP; Caress J; Katz J; McCauley JL; Rademakers R; Malaspina A; Ostrow LW; Wuu J;
    Neurology; 2020 Jul; 95(1):e59-e69. PubMed ID: 32385188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NfL and pNfH are increased in Friedreich's ataxia.
    Hayer SN; Liepelt I; Barro C; Wilke C; Kuhle J; Martus P; Schöls L;
    J Neurol; 2020 May; 267(5):1420-1430. PubMed ID: 32002649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics.
    Behzadi A; Pujol-Calderón F; Tjust AE; Wuolikainen A; Höglund K; Forsberg K; Portelius E; Blennow K; Zetterberg H; Andersen PM
    Sci Rep; 2021 Nov; 11(1):22128. PubMed ID: 34764380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.